Patent WO/2011/009890, 27.01.2011,
Aplicants: NOVARTIS AG [CH/CH]; FEUERBACH, Dominik [DE/CH]; GOMEZ-MANCILLA, Baltazar [MX/CH].
The invention concerns the use of azabicydoalkyl derivatives or pyrroiidine-2-one derivatives for the treatment, prevention or delay of progression of ataxia.
"FA, is one of the types of ataxia for which the applicants assume that this drug can be useful"
Wednesday, February 2, 2011
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment